Company
Headquarters: Tokyo, Japan
Founded: Doshomachi, Osaka, Japan June 12, 1781
Employees: 47,099
CEO: Mr. Christophe Weber
¥6.720 Trillion
JPY as of Jan. 1, 2024
US$47.71 Billion
Company | Market Cap (USD) |
---|---|
Zoetis Inc. | $89.09 B |
MERCK Kommanditgesellschaft auf Aktien | $67.64 B |
Haleon plc | $38.90 B |
PPD, Inc. | $16.58 B |
Eisai Co. Ltd | $14.86 B |
Company | Market Cap (USD) |
---|---|
Lilly | $586.39 B |
UnitedHealth Group | $504.47 B |
Novo Nordisk | $461.52 B |
Johnson & Johnson | $387.50 B |
Merck | $296.51 B |
Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, marketing, and out-licensing of pharmaceutical products worldwide. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the Entyvio, Gattex/Revestive, Alofisel, Natpara, Adynovate/Adynovi, Takhzyro, Elaprase, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Albumin/Flexbumin, Ninlaro, and Alunbrig brands. Takeda Pharmaceutical Company has licensing agreements with Denali Therapeutics and Wave Life Sciences Ltd; collaboration agreements with Neurocrine Biosciences, Inc. and Rani Therapeutics LLC; license and research agreements with The University of Texas MD Anderson Cancer Center, Poseida Therapeutics, Inc., and Arrowhead Pharmaceuticals Inc.; research collaboration agreements with Arrowhead Pharmaceuticals Inc. and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; HemoShear Therapeutics, LLC; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
Top 1-year algo backtest: +284.14%
$10,000 in April 2023 would now be $38,414 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Takeda Pharmaceutical Company Limited has the following listings and related stock indices.
Stock: JPX: 4502 wb_incandescent
Stock: FSX: TKD wb_incandescent
Stock: OTC: TKPHF wb_incandescent
Stock: NYSE: TAK wb_incandescent
Stock: BMV: TAKN wb_incandescent
Stock: XSTU: TKDA wb_incandescent
Stock: FSX: TKDA wb_incandescent
Founder(s): Chobei Takeda I
Yasuchika Hasegawa (Chairman of the Board) Christophe Weber (President & CEO)
Revenue: ¥1,770,531 million (FY 2018)[* 1]
Operating income: ¥241,789 million (FY 2018)[* 1]
Net income: ¥186,886 million (FY 2012)[* 1]
Total assets: ¥4,106,463 billion (FY 2018)[* 1]
Total equity: ¥1,997,424 billion (FY 2018)[* 1]